Microscopic Colitis
16
2
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.3%
1 terminated out of 16 trials
83.3%
-3.2% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
Enabling Microbiomics- Driven Personalized Nutrition
Chronic Diarrhea Owing to Underlying Microscopic Colitis
Systems Biology of Gastrointestinal and Related Diseases
Mucosa Adherent Intestinal Microbiome in Microscopic Colitis and Colorectal Cancer
Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis
External Validation of a Microscopic Colitis Clinical Scoring System in Patients With Chronic Watery Diarrhoea
Faecal Microbiota Transplantation for Microscopic Colitis
Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
Faecal Microbiota Transplantation in Patients With Microscopic Colitis
FMT in Inflammatory Bowel Disease
Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis
Case-Control Study to Identify Risk Factors for Microscopic Colitis
Trial of Mesalamine for the Treatment of Active Microscopic Colitis
Budesonide Treatment for Lymphocytic Colitis